ClinicalTrials.gg
RecruitingNCT03744819Updated Feb 6, 2024

Biomarkers for Prediction of Tumor Response to Radiotherapy

An observational study in Solid Tumors, sponsored by Chuangzhen Chen. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Chuangzhen Chen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2018; still recruiting 8 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Sex
All
01

Study summary

This study aims to explore potential biomarkers for prediction of therapeutic outcomes in patients with solid tumors after radiotherapy

Read the detailed description

Patients pathologically confirmed with solid tumors that requires radiotherapy or surgery will be recruited to this study. Tumor samples were obtained from patients underwent surgery to establish the baseline status of biomarker assessed. Peripheral and microbiota will also be collected before and after surgery. For patients undergoing radiotherapy, tumor biopsy as well as collection of blood samples and microbiota will be performed during the course of treatment. These biological specimens will be used for assessment of tumor phenotypes and for exploration of potential biomarkers that could predict the tumor response to therapeutics and prognsis in patients with solid tumors.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Chuangzhen Chen is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients proven diagnosis of solid tumors and will have radiotherapy as part of their therapeutic regimens or will undergo surgery in Cancer Hospital of Shantou University Medical College.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathological proven diagnosis of solid tumors
  • Tumor accessible for during the course of radiotherapy or tumor samples could be obtained via surgery
  • Patient must provide study-specific prior to study entry

Exclusion criteria

Exclusion Criteria:

  • History of diseases
  • History of immunotherapy
  • Prior radiation therapy that would result in overlap of planned radiation therapy fields
  • Will receive immunotherapy during the course of radiotherapy
  • for , such as high bleeding risk
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Expression status of biomarkers and their dynamic changes during treatment and follow-up

    Expression status of biomarkers and their dynamic changes in patients' biological specimens through the course of treatment and during follow-up as assessed by a variety of means, including RNA-seq, DNA-seq, RT-qPCR, IHC, WB and ELISA.

    Time frame: From the date of enrollment until the date of disease progression, assessed up to 3 years

  2. Tumor short-term response to therapeutics

    For patients treated with radiotherapy, shortly after the completion of treatment, the short-term response was assessed by using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) .

    Time frame: Within 1 month after the completion of radiotherapy

  3. Tumor long-term response to therapeutics

    For patients treated with radiotherapy, tumor response was assessed by using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) .

    Time frame: up to 3 years of follow-up

Secondary outcomes

  1. Disease-specific survival

    The tumor disease-specific survival of patients

    Time frame: up to 3 years of follow-up

Other outcomes

  1. Overall survival

    The overall survival of patients

    Time frame: up to 3 years of follow-up

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital, Shantou University Medical College
    Shantou, Guangdong 515031, China
    Recruiting
    • Chuangzhen Chen, MD · Contactstccz@139.com · 86-13923995569
    • Jianzhou Chen, MD · Contactcjzeoeo@gmail.com · 86-13417049908
    • Chuangzhen Chen, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2018 (actual). Primary completion is estimated for Nov 2025, 85 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2018
First posted
Nov 16, 2018
StartActual
Oct 29, 2018
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2026
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03744819
Lead sponsor
Chuangzhen Chen
Responsible party
Chuangzhen Chen (Deputy Director, Department of Radiation Oncology, Shantou University Medical College) — Sponsor-investigator
First posted
Nov 16, 2018
Start date
Oct 29, 2018
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Feb 6, 2024

Study contacts

Chuangzhen Chen, MD
Contact
stccz@139.com
+86 13923995569
Chuangzhen Chen, MD
principal investigator · Affiliated Cancer Hospital of Shantou University Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion